<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01069913</url>
  </required_header>
  <id_info>
    <org_study_id>109HV105</org_study_id>
    <nct_id>NCT01069913</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics Profile Study of BG00012 Standard Formulation and BG00012 Active Pharmaceutical Ingredient</brief_title>
  <official_title>A Pharmacokinetics Profile Determination of BG00012 Standard Formulation and the BG00012 Active Pharmaceutical Ingredient (API) After a Single Oral Dose Administered to Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to measure two different formulations of BG00012 to determine
      how much of each formulation of BG00012 reaches the blood stream and how long it takes the
      body to get rid of it, when given as a single dose.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK profiles of the current BG00012 standard formulation and the BG00012 API formulation in healthy volunteers. Primary PK parameter will be the area under the plasma concentration curve</measure>
    <time_frame>4 days post dosing period 2</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the safety and tolerability of the current oral BG00012 standard formulation and the encapsulated oral BG00012 API</measure>
    <time_frame>4 days after dosing period 2</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BG00012</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BG00012 Standard Formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BG00012 API</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BG00012 API</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BG00012</intervention_name>
    <description>Sequence 1: Oral 240 mg BG00012 Standard Formulation &amp; Following 7 day washout period, 240 mg BG00012 API.
Sequence 2: 240 mg BG00012 API &amp; Following 7 day washout period, 240 mg BG00012 Standard Formulation.</description>
    <arm_group_label>BG00012</arm_group_label>
    <arm_group_label>BG00012 API</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males 18 to 55 years old, inclusive, at the time of informed consent.

          2. Must weigh between 50 kg and 110 kg, inclusive.

          3. Must have a body mass index (BMI) between 19 kg/m2 and 30 kg/m2, inclusive.

          4. All subjects must practice effective contraception during the study and be willing and
             able to continue contraception for 30 days after their last dose of study treatment.

          5. Must be a non-smoker, and no use of chewing tobacco, for at least 6 months prior to
             Day -1.

          6. Must have a screening physical examination and ECG without any clinically significant
             abnormality (as determined by the Investigator).

        Exclusion Criteria:

          1. History of malignancy (subjects with basal cell carcinoma that has been completely
             excised prior to study entry remain eligible).

          2. History of severe allergic or anaphylactic reaction.

          3. History of any clinically significant endocrinologic, hematologic, hepatic,
             immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric,
             and renal, or other major diseases, as determined by the Investigator.

          4. Clinically significant abnormal hematology or blood chemistry values, as determined by
             the Investigator.

          5. Serious infection (e.g., pneumonia, septicemia) within the 2 months prior to Day -1.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Biogen Idec Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen Idec, Cambridge, MA USA</affiliation>
  </overall_official>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2010</study_first_submitted>
  <study_first_submitted_qc>February 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2010</study_first_posted>
  <last_update_submitted>February 16, 2010</last_update_submitted>
  <last_update_submitted_qc>February 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>Biogen Idec</name_title>
    <organization>Medical Director</organization>
  </responsible_party>
  <keyword>Healthy Volunteer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dimethyl Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

